Relay Therapeutics, Inc. (NASDAQ:RLAY) executive Peter Rahmer, the company's Chief Corporate Development Officer, recently sold shares in a transaction connected to the vesting of restricted stock ...
On Tuesday, Marker Therapeutics (NASDAQ:MRKR) stock received a Buy rating from Ladenburg Thalmann, accompanied by a price target of $11.00. The firm recognized the potential in the post-CAR-T ...
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for ...
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results